11/24/2025
"According to international guidelines, when a patient has localized prostate cancer treatment the conventional treatment options include radical prostatectomy (RP) and radiation therapy (RT), which treat the whole prostate regardless where the underlying pathology is located.
The comorbidity associated with this type of treatment in combination with a relatively high cancer specific survival (92%) has a tremendous impact on quality of life and cost.
Approximately 15–20% of the patients who undergo prostatectomy will suffer from treatment-induced urinary dysfunction and 8–36% will have to live with erectile dysfunction.”
Thankfully, TULSA provides comparable or better than outcomes for erectile dysfunction and urinary incontinence when compared to other prostate cancer treatment options. Read more in the article below, featuring Dr. Busch:
https://buschcenter.com/wp-content/uploads/Futterer_TULSA_MAGNETOM-Flash_RSNA_2020.pdf